Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Management of epistaxis in nine patients using systemic hormone therapy.
The combination of a progestogen and an estrogen (Enovid, Enovid E) has been used successfully in the management of nine patients with hereditary hemorrhagic telangiectasia (HHT) and severe epistaxis: Such therapy was instituted when epistaxis was severe and only after other therapeutic measures had failed. Seven of our patients required the 5-mg tablet (Enovid) to achieve a satisfactory clinical result; two patients received the 2.5-mg preparation (Enovid E). The eight women received cyclic therapy; the man received therapy without interruption. Because of the possibility of serious adverse effects from the drugs, it is required that each patient receive a complete medical evaluation prior to therapy and at frequent intervals while receiving therapy. Enovid therapy for HHT is not recommended for the patient with mild bleeding that can be controlled by conventional therapy.
D000328:Adult; D000368:Aged; D004338:Drug Combinations; D004844:Epistaxis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008656:Mestranol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009641:Norethynodrel / Q000009:adverse effects / Q000627:therapeutic use*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*
D004338:Drug Combinations; D009641:Norethynodrel; D008656:Mestranol